OAKLAND, Calif.--(BUSINESS WIRE)--

Girard Gibbs LLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ:OCUL) regarding possible securities law violations.

To speak privately with an attorney regarding this class action lawsuit investigation, click here.

Ocular Therapeutix disclosed on May 5, 2017 that it received a Form 483 from the U.S. Food and Drug Administration containing “inspectional observations” related to the Company’s manufacturing and analytical testing procedures.

On July 6, 2017, shortly before the end of the trading day, Seeking Alpha published an article reporting that the Ocular Therapeutix management may have misled investors regarding the severity of ongoing manufacturing issues and downplayed the significance of FDA communications regarding these issues.

Following this news, the company’s share price fell 6% on July 6, 2017, and plummeted an additional 25% on July 7, 2017 to $7.12, causing significant harm to investors.

If you purchased or acquired shares of Ocular Therapeutix, Inc. and would like to speak privately with a securities attorney to learn more about the investigation and your legal rights, visit our website or contact the securities team directly at (800) 254-9493.

Girard Gibbs LLP is one of the nation’s leading firms representing individual and institutional investors in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and has earned Tier-1 rankings and been named in the U.S. Lawyers – Best Law Firms list for five consecutive years.

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170707005720/en/